WHAT DO YOU GUYS THINK OF AZ NOW??

Quote

Anonymous

Guest
Now that it's been a few years since we bought you, just curious as to what you guys think of AZ and how has it affected your jobs at Medi and overall outlook for the future?
 


















Us AZ boys are getting ready to cut this company to pieces. We lost the patent on Seroquel yesterday. No a good thing. We way overpaid for this POS company and now it's time to cut our losses, and that means you!
 






quite funny, AZ has no pipeline and you think that by cutting Medi will help you..?
AZ has 50K+ people Medi will need to hold up the next couple years...that's alot of dead weight.
 






The reality is that the medi reps could take over the majority of AZ's products and do just as well here in the US so if more cuts are coming, it will be AZ that bleeds....sorry but true.
 


















Medimmune have a reasonably healthy pipeline; they just don't shout about it. I know there are some gaps (hence partnering in for late stage *now*) but they seem to be AZs only hope to deliver over the next few years. I believe Medi will deliver but not to the ridiculous levels that were set; no-one can achieve that! This leads me to believe that in 2 years there will be cuts at Medi sites.
However, I would ask people to remember that it wasn't just Medimmune that AZ bought - it was Cambridge Antibody Therapeutics (CAT) as well. CAT got rolled into Medimmune... sortof... Cambridge site is called Medi but is still separate enough to wonder if they will be sold off to pay the bills...
CAT had a very good track record, excellent project management and was a bargain.
Medimmune I am not so sure about; products were all bought in and over-priced.
Asta Zeneca I do not rate.
 












Anonymous said:
Now that it's been a few years since we bought you, just curious as to what you guys think of AZ and how has it affected your jobs at Medi and overall outlook for the future?
Click to expand...

Was the MedImmune name taken off the main building? I hope it was for structural safety puroposes and the name is not being changed to AstraZeneca Biologics.
 






Anonymous said:
and what have Medimmune launched in recent years?
Click to expand...

There is as much 'terror' in research as there is across the entire MedOrg (BJ if you know what I mean). Push 'anything' through is the mantra - hence, unless someone in either the IMED or the PDC has the guts - the candidates will be pushed through to development. Once in development, no one is willing to 'kill' an effort. Hence, smoke and mirrors continues across the product lifecycle. Only problem - nothing will ever be approved to market. Remember that disaster MOTA......................
 






Anonymous said:
There is as much 'terror' in research as there is across the entire MedOrg (BJ if you know what I mean). Push 'anything' through is the mantra - hence, unless someone in either the IMED or the PDC has the guts - the candidates will be pushed through to development. Once in development, no one is willing to 'kill' an effort. Hence, smoke and mirrors continues across the product lifecycle. Only problem - nothing will ever be approved to market. Remember that disaster MOTA......................
Click to expand...

Do you think there is terror/fear in the MedOrg? Terror in Medi's R&D group? If you answer honestly, then ask (and answer) these questions; how did it get to such a state, why has the situation been allowed to continue and who is responsible.
 






I do laugh I little inside when I see the Mantra all over the building

"We Are MedI. We Are For Patients."

maybe it should be changed to

"We Are MedI. We Are For Greenbacks."
 






with Brennan out of the picture it didn't' take long for the cuts to start hitting MedImmune:


AZN to Restructure Operations
By Zacks Equity Research | Zacks – Wed, Jul 18, 2012 2:45 PM


AstraZeneca PLC’s (AZN) global biologics division, MedImmune, is set to streamline its infectious disease and vaccines research, development and operations. As part of the restructuring, AstraZeneca is closing its California sites at Mountain View and Santa Clara. However, the company will keep its site at Hayward operational.

As a result of the restructuring, AstraZeneca expects that 300 positions will be impacted of which 100 will be shifted to the company’s other sites including Hayward. This operation is expected to be over in 2014.

AstraZeneca believes that the changes will help in innovation across its therapeutics areas and also aid product development. This will also result in reduction of fixed cost associated with the sites. The company reaffirmed its commitment to infectious diseases and vaccines research and development, mentioning that the changes will not affect the supply of vaccines.

Our Take

AstraZeneca is on the back foot due to generic competition faced by its many of its drugs. Arimidex, Toprol-XL, Seroquel IR and Merrem are already facing generic competition in the US. Additionally, Nexium generics are expected in the US in 2014. Generic competition was primarily responsible for the $2 billion loss of revenues in 2011.

Moreover, AstraZeneca’s drugs operate in a highly competitive environment. AstraZeneca’s lead drug, Crestor, primarily competes with Pfizer Inc.’s (PFE) Lipitor and Merck & Co. Inc.’s (MRK) Zocor/Vytorin. Nexium competes with Pfizer’s Protonix. The company is looking to drive the bottom-line through cost-cutting initiatives and share buybacks.

We currently have a Neutral recommendation on AstraZeneca. The stock carries a Zacks #3 Rank (Hold rating) in the short term.
 






Anonymous said:
Do you think there is terror/fear in the MedOrg? Terror in Medi's R&D group? If you answer honestly, then ask (and answer) these questions; how did it get to such a state, why has the situation been allowed to continue and who is responsible.
Click to expand...

Everyone knows what the problem except everyone is too afraid to speak about it. So it continues. The problem shall be referred to as Voldemort, (they who shall not be named or identified in any way); to be specific would result in Voldemort's minions who monitor CF removing the post/thread.

Voldemort has been responsible for the disruption/destruction of more than one individual’s career, and clearly leads by fear and intimidation. Have you been to a PDC meeting lately, a lot of room for discussion and alternative thinking/proposals? Voldemort has been responsible for R&D and the med org for more than a year, thought they were supposed to fix things. What do you expect, how many drugs has Voldemort gotten approved? None. How many FDA or EMA meetings has Voldemort been to never mind lead? 1 or 2 maybe?. Has Voldemort ever written an IND, NDA, MAA? None on their record. No time to review promotion requests (at least for one organization) because they have more important things to do, a constant flow of people out the door and a how many new molecules have emerged? What a mess. But yet Voldemort continues, maybe one day they will face the truth. Until then, good luck as the terror continues.
 












Good luck to home office and R&D folks. Now what really happens to commercial at field level. AZ already has pediatrics sale force. What about medi managed care folks and frm's? Any insights ?
 












Anonymous said:
AZ will soon merge Medi into their structure. Surprised it hasn't happened a long time ago. The new CEO is swinging his ax! Get ready!
Click to expand...

I'm the original AZ rep that warned you guys about AZ when you were bought by us. Now, once you are merged into our insane asylum, you will know what real misery feels like! Pascal is probably going to layoff tons of us, and you guys as well, in preparation of the merger into our structure. I warned you guys years ago of what was ahead. You should have listened.
 






Top Bottom
Back
Quote